Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tango Therapeutics (TNGX – Research Report), Aclaris Therapeutics (ACRS – Research Report) and Immunocore Holdings (IMCR – Research Report).
Tango Therapeutics (TNGX)
In a report issued on May 8, Andrew Berens from Leerink Partners reiterated a Buy rating on Tango Therapeutics, with a price target of $20.00. The company’s shares closed last Thursday at $7.77.
According to TipRanks.com, Berens is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tango Therapeutics with a $18.25 average price target, implying a 133.4% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Aclaris Therapeutics (ACRS)
Leerink Partners analyst Thomas Smith maintained a Hold rating on Aclaris Therapeutics on May 8 and set a price target of $2.00. The company’s shares closed last Thursday at $1.23, close to its 52-week low of $0.59.
According to TipRanks.com, Smith is a top 100 analyst with an average return of
Aclaris Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.00, implying a 63.9% upside from current levels. In a report issued on May 8, H.C. Wainwright also reiterated a Hold rating on the stock.
Immunocore Holdings (IMCR)
Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immunocore Holdings on May 8 and set a price target of $74.00. The company’s shares closed last Thursday at $59.85.
According to TipRanks.com, Chang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunocore Holdings with a $84.58 average price target, which is a 39.0% upside from current levels. In a report issued on May 8, Needham also maintained a Buy rating on the stock with a $81.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNGX:
- Tango Therapeutics reports Q1 EPS (35c), consensus (31c)
- Cantor starts Tango Therapeutics with Overweight on tumor pipeline
- Tango Therapeutics initiated with an Overweight at Cantor Fitzgerald
- Tango Therapeutics price target raised to $17 from $16 at H.C. Wainwright
- Navigating the AI Minefield: Tango Therapeutics’ Struggle with Security Risks and EU Regulations
